- The trend backdrop is active with a 2-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
RDC
GER
Week ended 07 Aug 2026
Weekly Investor Report
Redcare Pharmacy NV · Healthcare · Pharmaceutical Retailers
Latest close
62.85 EUR
2.4%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 16.9% above the Trend Line and sits at 44.4% of its 52-week range. The latest completed week returned 2.4%, after a 2.0% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 64/100. Near-term considerations: volume confirmation is below normal.
Setup score
39
out of 100
Latest Close
62.85 EUR
7 Aug 2026
1W Return
2.4%
latest completed week
4W Return
2.0%
short-term follow-through
12W Return
34.1%
quarterly tape
Trend Breadth
3.8%
2 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
2.4%
Latest completed week; four-week move 2.0%.
Indicator stack
9/66
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
64/100
16 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 16.9% above the Trend Line and sits at 44.4% of its 52-week range. The latest completed week returned 2.4%, after a 2.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3612-week average 0.17
12-week confirmation
Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership3/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.36Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 2.0% over four weeks, 34.1% over 12 weeks, and -38.5% over one year. The current trend has remained active for 2 consecutive weeks.
Performance by holding period
Active trend streak2 weeks
Active weeks in one year2
Trend breadth3.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.94Latest activity-pressure read.
Pressure change-16.8%Four-week change in activity pressure.
Leadership-5.94Latest relative-leadership reading.
RS change27.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 79%
Model confidence 74%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value24/100Relative valuation strength. Underlying universe rank 77; rank 1 is best.
Quality2/100Profitability and accounting quality. Underlying universe rank 99; rank 1 is best.
Momentum6/100Medium-term price momentum. Underlying universe rank 95; rank 1 is best.
Growth83/100Revenue and earnings growth. Underlying universe rank 18; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.4x Market value relative to trailing revenue.
- EV / EBITDA
- 33.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -6.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 21.9% Gross profit retained from each unit of revenue.
- Operating margin
- -0.8% Operating profit retained from revenue.
- Free-cash-flow margin
- -3.3% Free cash flow generated from revenue.
- Return on invested capital
- -2.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 24.1% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.0% Net share repurchases relative to market value.
- Shareholder yield
- -0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 5.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment64/100
Weighted news tone is positive across 16 relevant articles.
10 positive · 6 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-39.5%Distance below the 52-week high.
13-week volatility11.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+35.9%Week of 19 Jun.
Worst week-30.6%Week of 6 Mar.
Latest week+2.4%Week of 7 Aug.
Shape of recent returns
Strong gains9
Modest gains2
Flat weeks0
Modest losses5
Sharp losses10
Recent vol11.7%13-week weekly-return volatility.
Base vol10.5%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew7.7% / -7.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank30 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Pharmaceutical Retailers
4-week rank1 / 1
Group average2.0%
Trend breadth100.0%
Trend100.0%active weekly trend signals
MD100.0%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape32/100
Trend, activity pressure, participation, and risk combine to a 32/100 tape read.
Indicator analysis43/100Latest 12-week confirmation: trend 2/12, activity pressure 11/12, relative leadership 3/12.
Activity pressure 0.36; No reversal markers Factors7/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 87; Small Cap Core rank 85 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment64/100Weighted news tone is positive across 16 relevant articles.
REDCARE PHARMACY : Deutsche Bank gives a Buy rating Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 62.85 EUR | 2.4% | 53.77 EUR | 103.5 EUR | 0.94 | -5.94 | 310.0K | On |
| 31 Jul 2026 | 61.40 EUR | -7.0% | 53.86 EUR | 103.8 EUR | 1.05 | -6.94 | 541.6K | On |
| 24 Jul 2026 | 66.05 EUR | -2.0% | 54.02 EUR | 104.2 EUR | 1.10 | 0.93 | 262.9K | Off |
| 17 Jul 2026 | 67.40 EUR | 9.4% | 53.97 EUR | 104.4 EUR | 1.12 | 2.59 | 333.4K | Off |
| 10 Jul 2026 | 61.60 EUR | -13.4% | 53.93 EUR | 104.7 EUR | 1.13 | -8.24 | 549.2K | Off |
| 3 Jul 2026 | 71.10 EUR | 10.4% | 53.96 EUR | 104.9 EUR | 1.00 | 2.07 | 126.8K | Off |
| 26 Jun 2026 | 64.40 EUR | -2.9% | 53.66 EUR | 105.2 EUR | 0.82 | -4.26 | 117.8K | Off |
| 19 Jun 2026 | 66.35 EUR | 35.9% | 53.70 EUR | 105.4 EUR | 0.61 | -3.40 | 501.1K | Off |
| 12 Jun 2026 | 48.82 EUR | 1.0% | 53.49 EUR | 105.5 EUR | 0.31 | -28.48 | 83.2K | Off |
| 5 Jun 2026 | 48.32 EUR | 10.7% | 53.92 EUR | 105.8 EUR | 0.15 | -30.50 | 125.4K | Off |
| 29 May 2026 | 43.64 EUR | -2.1% | 54.35 EUR | 106.0 EUR | 0.05 | -39.00 | 625.9K | Off |
| 22 May 2026 | 44.58 EUR | -4.9% | 55.27 EUR | 106.4 EUR | -0.02 | -38.40 | 586.6K | Off |
| 15 May 2026 | 46.86 EUR | 6.1% | 56.46 EUR | 106.7 EUR | -0.03 | -34.24 | 557.0K | Off |
| 8 May 2026 | 44.18 EUR | -8.7% | 57.68 EUR | 107.0 EUR | -0.01 | -40.24 | 907.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.